Discoveries in Lung Cancer

Discoveries in Lung Cancer

Source:

Spigel DR, et al. Abstract 8511. Presented at: 2021 ASCO Annual Meeting; June 4-8, 2021 (virtual meeting).

Disclosures: Spigel reports serving in a consulting or advisory role for Amgen (Inst), Aptitude Health (Inst), AstraZeneca (Inst), Bayer (Inst), Bristol Myers Squibb (Inst), Celgene (Inst), Curio Science (Inst), Dracen (Inst), EMD Serono (Inst), Evelo Therapeutics (Inst), Exelixis (Inst), Genentech/Roche (Inst), GlaxoSmithKline (Inst), Iksuda Therapeutics (Inst), Illumina (Inst), Intellisphere (Inst), Ipsen (Inst), Jazz Pharmaceuticals (Inst), Merck (Inst), Mirati Therapeutics (Inst), Molecular Templates (Inst), Nektar (Inst), Novartis (Inst), Novocure (Inst), Pfizer (Inst), PharmaMar (Inst), Puma Biotechnology (Inst), Regeneron (Inst), Sanofi/Aventis (Inst), Seattle Genetics (Inst), Takeda (Inst), TRIPTYCH Health Partners (Inst) and TRM Oncology (Inst); receiving research funding from Aeglea Biotherapeutics (Inst), Agios (Inst), Apollomics (Inst), Astellas Pharma (Inst), AstraZeneca (Inst), BIND Therapeutics (Inst), Bristol Myers Squibb (Inst), Calithera Biosciences (Inst), Celgene (Inst), Celldex (Inst), Clovis Oncology (Inst), cyteir (Inst), Daiichi Sankyo (Inst), Eisai (Inst), Elevation Oncology (Inst), EMD Serono (Inst), G1 Therapeutics (Inst), Genentech/Roche (Inst), GlaxoSmithKline (Inst), GRAIL (Inst), ImClone Systems (Inst), Immunogen (Inst), Ipsen (Inst), Janssen Oncology (Inst), Lilly (Inst), MedImmune (Inst), Merck (Inst), Molecular Partners (Inst), Nektar (Inst), Neon Therapeutics (Inst), Novartis (Inst), Novocure (Inst), Takeda (Inst), Tesaro (Inst), Transgene (Inst) and The University of Texas Southwestern Medical Center – Simmons Cancer Center (Inst); and receiving travel, accommodations and/or expenses from AstraZeneca, Genentech and Novartis. Please see the abstract for all other authors’ disclosures.
June 27, 2021
1 min read
Save

PACIFIC trial update: 5-year survival outcomes with durvalumab after chemoradiation

Source:

Spigel DR, et al. Abstract 8511. Presented at: 2021 ASCO Annual Meeting; June 4-8, 2021 (virtual meeting).

Disclosures: Spigel reports serving in a consulting or advisory role for Amgen (Inst), Aptitude Health (Inst), AstraZeneca (Inst), Bayer (Inst), Bristol Myers Squibb (Inst), Celgene (Inst), Curio Science (Inst), Dracen (Inst), EMD Serono (Inst), Evelo Therapeutics (Inst), Exelixis (Inst), Genentech/Roche (Inst), GlaxoSmithKline (Inst), Iksuda Therapeutics (Inst), Illumina (Inst), Intellisphere (Inst), Ipsen (Inst), Jazz Pharmaceuticals (Inst), Merck (Inst), Mirati Therapeutics (Inst), Molecular Templates (Inst), Nektar (Inst), Novartis (Inst), Novocure (Inst), Pfizer (Inst), PharmaMar (Inst), Puma Biotechnology (Inst), Regeneron (Inst), Sanofi/Aventis (Inst), Seattle Genetics (Inst), Takeda (Inst), TRIPTYCH Health Partners (Inst) and TRM Oncology (Inst); receiving research funding from Aeglea Biotherapeutics (Inst), Agios (Inst), Apollomics (Inst), Astellas Pharma (Inst), AstraZeneca (Inst), BIND Therapeutics (Inst), Bristol Myers Squibb (Inst), Calithera Biosciences (Inst), Celgene (Inst), Celldex (Inst), Clovis Oncology (Inst), cyteir (Inst), Daiichi Sankyo (Inst), Eisai (Inst), Elevation Oncology (Inst), EMD Serono (Inst), G1 Therapeutics (Inst), Genentech/Roche (Inst), GlaxoSmithKline (Inst), GRAIL (Inst), ImClone Systems (Inst), Immunogen (Inst), Ipsen (Inst), Janssen Oncology (Inst), Lilly (Inst), MedImmune (Inst), Merck (Inst), Molecular Partners (Inst), Nektar (Inst), Neon Therapeutics (Inst), Novartis (Inst), Novocure (Inst), Takeda (Inst), Tesaro (Inst), Transgene (Inst) and The University of Texas Southwestern Medical Center – Simmons Cancer Center (Inst); and receiving travel, accommodations and/or expenses from AstraZeneca, Genentech and Novartis. Please see the abstract for all other authors’ disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Giving durvalumab to patients with stage III non-small cell lung cancer after chemoradiation reduced the risk for death and disease progression, according to data 5 years after initiation of the PACIFIC trial.

David R. Spigel, MD, chief scientific officer at Sarah Cannon Research Institute, shared an updated analysis on the trial at the virtual 2021 ASCO Annual Meeting.

“These findings transform the treatment landscape for unresectable stage III disease and establish durvalumab following chemoradiotherapy as the new standard of care,” Spigel said in the presentation.

Spigel and colleagues randomly assigned 713 patients with stage III non-small cell lung cancer (NSCLC), without progression following chemoradiotherapy, to receive durvalumab 10 mg/kg every 2 weeks for up to a year, or a placebo.

The researchers stopped collecting data on January 11, 2021, noting 58.8% of patients died by that date (durvalumab group, 55%; placebo group, 65%).

According to the presentation, 43% of patients taking durvalumab were alive 5 years after randomization, compared with 33% of patients assigned placebo.

“These updated results based on 5-year data from the PACIFIC trial demonstrate robust and sustained overall survival and durable PFS benefits with PACIFIC regimen,” Spigel said in the presentation. “An estimated 43% of patients in the durvalumab arm remain alive at 5 years from randomization and approximately one-third remain alive and free of disease progression.”

Durvalumab improved both overall and progression-free survival in the 5-year study.

“This establishes a new benchmark for the standard of care in the unresectable stage III non-small-cell lung cancer setting,” Spigel concluded. “The PACIFIC regimen is being investigated in combination with different chemoradiotherapy regimens as well as with other agents following chemoradiotherapy.”